Grandbridge 2011 Annual Report During the period, potentially...

Grandbridge 2011 Annual Report

During the period, potentially new anti-mitoticmicrotubule candidate compounds were identifiedby MDSystems’ Principal Researcher Dr Robin Scaifefollowing progression through the screening process atMDSystems. Targeting of cancer cell proliferation throughmitotic inhibition has been demonstrated by these earlystage candidate compounds.

Cortical Dynamics continued to develop its BrainAnaesthesia Monitoring (BAR) device with production ofcomplete BAR monitors during the year. End to end trialsusing the hypnotic benzodiazepine agent Alprazolamwere completed. The study demonstrated that the majorcomponents of the BAR system were capable of robustlyreplicating the well known pharmaco-EEG phenomenaof benzodiazepine agents, the benzodiazepine-induced“beta buzz”. In more recent developments,

Cortical Dynamicscommenced its Initial Public Offering (IPO) and hasapplied for admission to the Official List of the AustralianSecurities Exchange (ASX).

Full of anticipation, we look forward to the excitingyear ahead.

Yours faithfully David Breeze Executive Chairman Investment Advisory

Grandbridge 2011 Annual Report